Many biotech companies have raised significantly more capital through Y Combinator than they would have in traditional biotech venture settings, with over $200 million raised for these companies.

Being part of Y Combinator provides invaluable exposure and credibility, especially for founders who may not have connections in Silicon Valley. It creates a unique momentum during fundraising, culminating in a demo day where you can present to top investors.

Y Combinator is not just an investment firm; it's a collection of people, both founders and partners, curated over the past decade.

The likelihood of securing Series A funding is significantly higher for Y Combinator startups, with 45% achieving this milestone compared to the industry average of 33%.

Four companies—Airbnb, Coinbase, Reddit, and Instacart—account for over 85% of Y Combinator's returns, illustrating the VC power law in action.

In early-stage investing, the ability to evaluate founders effectively is a significant advantage, and this skill has been crucial to Y Combinator's success.

Y Combinator is playing a significant role in funding young entrepreneurs in the biotech space, allowing them to advance their discoveries.

At Y Combinator, we invest in founders at the idea stage, understanding that it may take over a decade to see if their concepts are viable, so short-term valuations are less critical.

Biotech companies benefit from Y Combinator through access to capital, fundraising expertise, and interaction with diverse sectors, which can lead to unexpected advantages.